Alnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to post its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($0.51) per share for the quarter. Alnylam Pharmaceuticals has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same period in the prior year, the company posted ($2.21) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $294.87 on Thursday. The company has a 50-day moving average of $273.47 and a two-hundred day moving average of $220.04. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The stock has a market cap of $37.30 billion, a price-to-earnings ratio of -110.03 and a beta of 0.39.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ALNY. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, October 10th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday. Six investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $290.86.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock valued at $13,595,460 in the last 90 days. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.